A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III G… (NCT07517211) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
United States72 participantsStarted 2026-05-01
Plain-language summary
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \* Adults ≥ 18 years old at the start of study treatment.
* New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.
* Plan to start systemic therapy for resectable or potentially resectable disease.
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
* \* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.
* Metastatic disease at the time of diagnosis.
* Patients who are unable to provide informed consent.
* Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
* Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.
What they're measuring
1
Change in SPPB
Timeframe: Through the end of cancer treatment, an average of 6 months